These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 35190335)

  • 41. Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
    Castro E; Mateo J; Olmos D; de Bono JS
    Cancer J; 2016; 22(5):353-356. PubMed ID: 27749330
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in
    Chakraborty G; Patail NK; Hirani R; Nandakumar S; Mazzu YZ; Yoshikawa Y; Atiq M; Jehane LE; Stopsack KH; Lee GM; Abida W; Morris MJ; Mucci LA; Danila D; Kantoff PW
    Clin Cancer Res; 2021 Mar; 27(6):1792-1806. PubMed ID: 33334906
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
    Slootbeek PHJ; Duizer ML; van der Doelen MJ; Kloots ISH; Kuppen MCP; Westgeest HM; Uyl-de Groot CA; Pamidimarri Naga S; Ligtenberg MJL; van Oort IM; Gerritsen WR; Schalken JA; Kroeze LI; Bloemendal HJ; Mehra N
    Int J Cancer; 2021 Jan; 148(2):385-395. PubMed ID: 32965028
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Poly (ADP-ribose) polymerase inhibitors (PARPi) for advanced malignancies with multiple DNA-repair genetic aberrations.
    Hu J; Liang P; Jin D; Fan R; Xie X; Liu C; Jiang Q; Gao L
    Expert Rev Anticancer Ther; 2022 Jul; 22(7):717-723. PubMed ID: 35679134
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pilot Study: PARP1 Imaging in Advanced Prostate Cancer.
    Dehdashti F; Reimers MA; Shoghi KI; Chen DL; Luo J; Rogers B; Pachynski RK; Sreekumar S; Weimholt C; Zhou D
    Mol Imaging Biol; 2022 Dec; 24(6):853-861. PubMed ID: 35701722
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials.
    Iannantuono GM; Chandran E; Floudas CS; Choo-Wosoba H; Butera G; Roselli M; Gulley JL; Karzai F
    Cancer Treat Rev; 2023 Nov; 120():102623. PubMed ID: 37716332
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence.
    Ditonno F; Bianchi A; Malandra S; Porcaro AB; Fantinel E; Negrelli R; Ferro M; Milella M; Brunelli M; Autorino R; Cerruto MA; Veccia A; Antonelli A
    Clin Genitourin Cancer; 2024 Apr; 22(2):402-412.e17. PubMed ID: 38281877
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Poly (ADP-ribose) Polymerase Inhibitors in Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Chao Z; Wang Z; Li L; Jiang Y; Tang Y; Wang Y; Hao X; Zhang C; Guo X; Yu W; Cheng F; Wang Z
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138301
    [No Abstract]   [Full Text] [Related]  

  • 49. The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.
    Pham MM; Hinchcliff E; Avila M; Westin SN
    Cancer J; 2021 Nov-Dec 01; 27(6):491-500. PubMed ID: 34904812
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells.
    Uddin MH; Li Y; Khan HY; Muqbil I; Aboukameel A; Sexton RE; Reddy S; Landesman Y; Kashyap T; Azmi AS; Heath EI
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206543
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.
    Gong J; Posadas E; Bhowmick N; Kim H; Daskivich T; Gupta A; Sandler H; Kamrava M; Zumsteg Z; Freedland S; Figlin R
    Oncology (Williston Park); 2021 Mar; 35(3):119-125. PubMed ID: 33818052
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
    Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer.
    Agarwal N; Zhang T; Efstathiou E; Sayegh N; Engelsberg A; Saad F; Fizazi K
    Eur J Cancer; 2023 Oct; 192():113249. PubMed ID: 37672815
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate Cancer.
    Yadav A; Biswas T; Praveen A; Ganguly P; Bhattacharyya A; Verma A; Datta D; Ateeq B
    Cancer Res Commun; 2023 Oct; 3(10):2044-2061. PubMed ID: 37812088
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer.
    Gonzalez D; Mateo J; Stenzinger A; Rojo F; Shiller M; Wyatt AW; Penault-Llorca F; Gomella LG; Eeles R; Bjartell A
    J Pathol Clin Res; 2021 Jul; 7(4):311-325. PubMed ID: 33630412
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanisms of PARP Inhibitor Resistance.
    O'Connor MJ; Forment JV
    Cancer Treat Res; 2023; 186():25-42. PubMed ID: 37978129
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
    Chu YY; Yam C; Yamaguchi H; Hung MC
    J Biomed Sci; 2022 Oct; 29(1):86. PubMed ID: 36284291
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer.
    Maughan BL; Antonarakis ES
    Expert Opin Pharmacother; 2021 Aug; 22(12):1625-1632. PubMed ID: 33827356
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations.
    Teply BA; Antonarakis ES
    Expert Rev Clin Pharmacol; 2022 Nov; 15(11):1293-1304. PubMed ID: 36285641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.